Using MAD7 and dMAD7 to improve gene editing tools for Bacillus subtilis

Editing rates of 93% and 100% were established using the MAD7 nuclease for gene editing in Bacillus subtilis.

• MAD7 is a newly available CRISPR nuclease that can be used without licensing fees for industrial research and development.
• The first catalytically inactive variant of MAD7 (dMAD7) was engineered, demonstrating its potential for gene regulation.
• dMAD7 achieved up to 71.3% reduction in gene expression at single and multiple target sites in B. subtilis.
• The research confirmed that the DNA double-strand breaks induced by the nuclease facilitate selection during gene editing.

Simplified